Grant intended to support manufacturing and development for rVSV-EBOV, including a new 330-person Phase Ib study
Sponsored Content Brought to you by Having been in the industry for more than 25 years, Patrick Guertin knows that cells can be temperamental and don’t like to be rushed, but in today’s biopharma industry speed to...
Glycan-binding anti-inflammatory protein designed to block activation of neutrophils.
Firm is looking for alternative platform to CEF manufacture for clinical-stage cancer and infectious disease vaccines.
Samsung Biologics and Bristol-Myers Squibb have entered into a 10-year agreement under which Samsung will manufacture an antibody cancer drug for BMS.
Automation is key to facilitating the availability of samples for research.
PEI transfection reagents are designed to enable protein production in the medium-to-large scale ranges.
Virosome-based vaccine is in early clinical development for treating chronic recurrent thrush.
Please wait while you are redirected to the right page...